As the last PR didn't include much data about the
Post# of 148278
(Total Views: 608)
Posted On: 01/06/2022 3:08:48 PM
As the last PR didn't include much data about the NASH 350mg and we await the 700mg topline report, you gotta wonder what the reaction would have been if the PR *only* mentioned we hit the primary endpoint.
Much of the doom and gloom seemed to stem from missing Secondary Endpoint. Did the SE legally have to be included? Surely could have at least buried it in the PR as folks seem so reactive to the headlines.
Just curious how market would have reacted to this headline:
Leronlimab 14-week NASH Clinical Trial Met Primary Endpoint in 350 mg Weekly Dose.
Much of the doom and gloom seemed to stem from missing Secondary Endpoint. Did the SE legally have to be included? Surely could have at least buried it in the PR as folks seem so reactive to the headlines.
Just curious how market would have reacted to this headline:
Leronlimab 14-week NASH Clinical Trial Met Primary Endpoint in 350 mg Weekly Dose.
(9)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼